Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 9 | 2025 | 849 | 1.730 |
Why?
|
| Methotrexate | 8 | 2025 | 344 | 1.630 |
Why?
|
| Rhabdomyosarcoma | 3 | 2025 | 228 | 1.040 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2025 | 188 | 0.820 |
Why?
|
| Neurotoxicity Syndromes | 4 | 2025 | 66 | 0.800 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.690 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1618 | 0.500 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2026 | 60 | 0.440 |
Why?
|
| Child | 22 | 2026 | 26332 | 0.370 |
Why?
|
| Bayes Theorem | 3 | 2023 | 307 | 0.370 |
Why?
|
| Catheter-Related Infections | 2 | 2024 | 137 | 0.350 |
Why?
|
| Adolescent | 15 | 2026 | 21008 | 0.260 |
Why?
|
| Child, Preschool | 11 | 2026 | 15066 | 0.250 |
Why?
|
| Prognosis | 5 | 2025 | 4961 | 0.220 |
Why?
|
| Laxatives | 1 | 2024 | 10 | 0.220 |
Why?
|
| Infant | 9 | 2026 | 13332 | 0.220 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 39 | 0.220 |
Why?
|
| Anti-Retroviral Agents | 1 | 2026 | 153 | 0.210 |
Why?
|
| Creatinine | 2 | 2023 | 402 | 0.210 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 49 | 0.210 |
Why?
|
| Proportional Hazards Models | 2 | 2025 | 1406 | 0.210 |
Why?
|
| Sarcoma, Kaposi | 1 | 2025 | 130 | 0.200 |
Why?
|
| Constipation | 1 | 2024 | 130 | 0.200 |
Why?
|
| Models, Statistical | 1 | 2026 | 493 | 0.200 |
Why?
|
| von Willebrand Diseases | 1 | 2023 | 55 | 0.190 |
Why?
|
| Health Information Systems | 1 | 2022 | 31 | 0.190 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 52 | 0.180 |
Why?
|
| Warfarin | 1 | 2023 | 123 | 0.180 |
Why?
|
| von Willebrand Factor | 1 | 2023 | 192 | 0.180 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2022 | 32 | 0.180 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 52 | 0.180 |
Why?
|
| Humans | 24 | 2026 | 131967 | 0.180 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 69 | 0.180 |
Why?
|
| Wilms Tumor | 1 | 2023 | 120 | 0.180 |
Why?
|
| Retrospective Studies | 9 | 2026 | 17703 | 0.180 |
Why?
|
| Risk Factors | 4 | 2026 | 10998 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2025 | 379 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2025 | 1281 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1357 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2023 | 499 | 0.150 |
Why?
|
| Malawi | 3 | 2026 | 339 | 0.150 |
Why?
|
| Cross Infection | 1 | 2022 | 339 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2022 | 317 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 453 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2024 | 708 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 115 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 252 | 0.140 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1319 | 0.130 |
Why?
|
| Male | 12 | 2026 | 65357 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 200 | 0.130 |
Why?
|
| Female | 12 | 2026 | 71316 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2019 | 189 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1264 | 0.120 |
Why?
|
| Age Factors | 1 | 2021 | 2869 | 0.110 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 537 | 0.100 |
Why?
|
| Thrombosis | 1 | 2019 | 495 | 0.100 |
Why?
|
| HIV Infections | 1 | 2026 | 2042 | 0.100 |
Why?
|
| Incidence | 3 | 2026 | 3352 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 5298 | 0.090 |
Why?
|
| Mutation | 1 | 2025 | 6200 | 0.080 |
Why?
|
| Neoplasms | 1 | 2026 | 2965 | 0.080 |
Why?
|
| Chronic Disease | 2 | 2026 | 1239 | 0.080 |
Why?
|
| Young Adult | 4 | 2025 | 10108 | 0.080 |
Why?
|
| Anticoagulants | 2 | 2024 | 597 | 0.070 |
Why?
|
| Survival Rate | 2 | 2025 | 2154 | 0.070 |
Why?
|
| Platelet Count | 1 | 2026 | 140 | 0.060 |
Why?
|
| Oral Health | 1 | 2024 | 28 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2024 | 159 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 203 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2023 | 46 | 0.050 |
Why?
|
| Ferritins | 1 | 2023 | 109 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 66 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2022 | 84 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2022 | 47 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2023 | 314 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 102 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2023 | 175 | 0.040 |
Why?
|
| Machine Learning | 1 | 2025 | 375 | 0.040 |
Why?
|
| Recurrence | 1 | 2025 | 1487 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 998 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 590 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1261 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1325 | 0.040 |
Why?
|
| Heart Rate | 1 | 2022 | 580 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 460 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 214 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 207 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5122 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1916 | 0.020 |
Why?
|
| Echocardiography | 1 | 2019 | 1138 | 0.020 |
Why?
|
| Time Factors | 1 | 2022 | 6285 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3928 | 0.020 |
Why?
|
| United States | 1 | 2022 | 11827 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 13011 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8604 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 31734 | 0.010 |
Why?
|